Ireland

Ireland

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.62 (0.50 - 0.74) 2019 Modelled IHME
0.65 (0.52 - 0.76) 2018 Modelled IHME
0.66 (0.53 - 0.79) 2017 Modelled IHME
0.66 (0.53 - 0.79) 2016 Modelled IHME
0.66 (0.53 - 0.80) 2015 Modelled IHME
0.67 (0.54 - 0.80) 2014 Modelled IHME
0.67 (0.55 - 0.80) 2013 Modelled IHME
0.68 (0.56 - 0.81) 2012 Modelled IHME
0.69 (0.56 - 0.82) 2011 Modelled IHME
0.7 (0.57 - 0.83) 2010 Modelled IHME
0.71 (0.58 - 0.84) 2009 Modelled IHME
0.72 (0.59 - 0.85) 2008 Modelled IHME
0.73 (0.59 - 0.86) 2007 Modelled IHME
0.74 (0.60 - 0.88) 2006 Modelled IHME
0.75 (0.60 - 0.89) 2005 Modelled IHME
0.75 (0.61 - 0.89) 2004 Modelled IHME
0.75 (0.61 - 0.90) 2003 Modelled IHME
0.75 (0.61 - 0.91) 2002 Modelled IHME
0.75 (0.61 - 0.91) 2001 Modelled IHME
0.75 (0.62 - 0.92) 2000 Modelled IHME
0.76 (0.63 - 0.93) 1999 Modelled IHME
0.77 (0.63 - 0.93) 1998 Modelled IHME
0.78 (0.64 - 0.94) 1997 Modelled IHME
0.78 (0.64 - 0.95) 1996 Modelled IHME
0.79 (0.64 - 0.95) 1995 Modelled IHME
0.79 (0.65 - 0.95) 1994 Modelled IHME
0.79 (0.65 - 0.95) 1993 Modelled IHME
0.79 (0.65 - 0.95) 1992 Modelled IHME
0.79 (0.64 - 0.96) 1991 Modelled IHME
0.79 (0.63 - 0.96) 1990 Modelled IHME
0.1 (0.10 - 0.40) 2009 Survey/reported Talento AF, 2010
0.1 (0 - 0.40) 2003 Survey/reported Nardone A et al, 2009
0.04 (0.02 - 0.07) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.04) 2019 Modelled IHME
0.03 (0.02 - 0.05) 2018 Modelled IHME
0.03 (0.02 - 0.05) 2017 Modelled IHME
0.03 (0.02 - 0.05) 2016 Modelled IHME
0.04 (0.02 - 0.05) 2015 Modelled IHME
0.04 (0.03 - 0.06) 2014 Modelled IHME
0.06 (0.04 - 0.08) 2013 Modelled IHME
0.09 (0.06 - 0.11) 2012 Modelled IHME
0.11 (0.07 - 0.15) 2011 Modelled IHME
0.14 (0.09 - 0.19) 2010 Modelled IHME
0.18 (0.11 - 0.24) 2009 Modelled IHME
0.24 (0.15 - 0.32) 2008 Modelled IHME
0.29 (0.19 - 0.40) 2007 Modelled IHME
0.34 (0.23 - 0.46) 2006 Modelled IHME
0.36 (0.24 - 0.49) 2005 Modelled IHME
0.35 (0.24 - 0.49) 2004 Modelled IHME
0.35 (0.24 - 0.48) 2003 Modelled IHME
0.35 (0.24 - 0.48) 2002 Modelled IHME
0.35 (0.24 - 0.47) 2001 Modelled IHME
0.35 (0.23 - 0.48) 2000 Modelled IHME
0.35 (0.24 - 0.48) 1999 Modelled IHME
0.36 (0.24 - 0.48) 1998 Modelled IHME
0.37 (0.26 - 0.49) 1997 Modelled IHME
0.38 (0.26 - 0.51) 1996 Modelled IHME
0.39 (0.26 - 0.52) 1995 Modelled IHME
0.39 (0.27 - 0.52) 1994 Modelled IHME
0.39 (0.27 - 0.52) 1993 Modelled IHME
0.39 (0.27 - 0.53) 1992 Modelled IHME
0.38 (0.26 - 0.53) 1991 Modelled IHME
0.38 (0.24 - 0.54) 1990 Modelled IHME
0.01 (0 - 0.02) 2015 Modelled WHO
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
0.3 (0 - 0.90) 2011 Survey/reported Drummond A et al, 2014.

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (8 - 17) 2019 Modelled IHME
12 (8 - 18) 2018 Modelled IHME
12 (8 - 18) 2017 Modelled IHME
12 (8 - 18) 2016 Modelled IHME
12 (8 - 18) 2015 Modelled IHME
12 (8 - 18) 2014 Modelled IHME
12 (9 - 18) 2013 Modelled IHME
13 (9 - 18) 2012 Modelled IHME
13 (9 - 18) 2011 Modelled IHME
13 (9 - 18) 2010 Modelled IHME
13 (9 - 18) 2009 Modelled IHME
13 (9 - 18) 2008 Modelled IHME
12 (9 - 18) 2007 Modelled IHME
12 (8 - 18) 2006 Modelled IHME
12 (8 - 18) 2005 Modelled IHME
12 (8 - 18) 2004 Modelled IHME
12 (8 - 17) 2003 Modelled IHME
12 (8 - 17) 2002 Modelled IHME
12 (8 - 17) 2001 Modelled IHME
12 (8 - 17) 2000 Modelled IHME
12 (8 - 17) 1999 Modelled IHME
12 (8 - 18) 1998 Modelled IHME
12 (8 - 18) 1997 Modelled IHME
12 (8 - 18) 1996 Modelled IHME
12 (8 - 18) 1995 Modelled IHME
12 (8 - 18) 1994 Modelled IHME
12 (8 - 18) 1993 Modelled IHME
13 (9 - 18) 1992 Modelled IHME
13 (9 - 18) 1991 Modelled IHME
13 (9 - 18) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
94 2018 Survey/reported WHO/UNICEF
95 2017 Survey/reported WHO/UNICEF
95 2016 Survey/reported WHO/UNICEF
95 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
46 2010 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
46 (37 - 62) 2014 Survey/reported Health Research Board, 2014

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.74 (0.61 - 0.91) 2019 Modelled IHME
0.73 (0.60 - 0.90) 2018 Modelled IHME
0.73 (0.59 - 0.90) 2017 Modelled IHME
0.71 (0.59 - 0.87) 2016 Modelled IHME
0.7 (0.57 - 0.87) 2015 Modelled IHME
0.7 (0.58 - 0.86) 2014 Modelled IHME
0.7 (0.57 - 0.86) 2013 Modelled IHME
0.7 (0.57 - 0.85) 2012 Modelled IHME
0.7 (0.57 - 0.85) 2011 Modelled IHME
0.7 (0.57 - 0.86) 2010 Modelled IHME
0.69 (0.57 - 0.85) 2009 Modelled IHME
0.69 (0.57 - 0.84) 2008 Modelled IHME
0.69 (0.56 - 0.84) 2007 Modelled IHME
0.68 (0.55 - 0.83) 2006 Modelled IHME
0.68 (0.55 - 0.83) 2005 Modelled IHME
0.67 (0.55 - 0.82) 2004 Modelled IHME
0.67 (0.55 - 0.82) 2003 Modelled IHME
0.66 (0.54 - 0.82) 2002 Modelled IHME
0.66 (0.54 - 0.82) 2001 Modelled IHME
0.65 (0.53 - 0.81) 2000 Modelled IHME
0.64 (0.52 - 0.80) 1999 Modelled IHME
0.64 (0.52 - 0.79) 1998 Modelled IHME
0.63 (0.51 - 0.78) 1997 Modelled IHME
0.62 (0.50 - 0.76) 1996 Modelled IHME
0.62 (0.50 - 0.75) 1995 Modelled IHME
0.61 (0.50 - 0.75) 1994 Modelled IHME
0.61 (0.49 - 0.74) 1993 Modelled IHME
0.6 (0.49 - 0.74) 1992 Modelled IHME
0.6 (0.49 - 0.74) 1991 Modelled IHME
0.6 (0.48 - 0.74) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.1 (0 - 0.40) 2009 Survey/reported Talento AF, 2010
1.1 (0.70 - 1.60) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
41.5 (34.60 - 48.70) 2010 Survey/reported EMCDDA
74.6 (72.30 - 76.90) 2003 Modelled Nelson P et al, 2011
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
12.9 (10.60 - 15.40) 2014 Survey/reported Drummond A et al, 2014.

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
39 (29 - 49) 2019 Modelled IHME
39 (30 - 49) 2018 Modelled IHME
39 (29 - 50) 2017 Modelled IHME
39 (30 - 49) 2016 Modelled IHME
39 (30 - 49) 2015 Modelled IHME
40 (30 - 49) 2014 Modelled IHME
39 (30 - 49) 2013 Modelled IHME
39 (30 - 49) 2012 Modelled IHME
39 (30 - 48) 2011 Modelled IHME
39 (29 - 48) 2010 Modelled IHME
38 (29 - 48) 2009 Modelled IHME
38 (29 - 48) 2008 Modelled IHME
38 (29 - 48) 2007 Modelled IHME
38 (29 - 48) 2006 Modelled IHME
39 (29 - 48) 2005 Modelled IHME
38 (29 - 48) 2004 Modelled IHME
38 (29 - 48) 2003 Modelled IHME
38 (29 - 48) 2002 Modelled IHME
38 (29 - 48) 2001 Modelled IHME
38 (28 - 48) 2000 Modelled IHME
38 (28 - 47) 1999 Modelled IHME
38 (28 - 48) 1998 Modelled IHME
38 (28 - 48) 1997 Modelled IHME
38 (28 - 48) 1996 Modelled IHME
38 (28 - 48) 1995 Modelled IHME
38 (28 - 48) 1994 Modelled IHME
39 (29 - 49) 1993 Modelled IHME
39 (29 - 49) 1992 Modelled IHME
39 (29 - 49) 1991 Modelled IHME
39 (29 - 49) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (37 - 62) 2014 Survey/reported Health Research Board, 2014

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.62 (%)
2019
(0.5 - 0.74(%))
IHME
HCV (RNA/cAg+)
0.74 (%)
2019
(0.61 - 0.91(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.1 (%)
2009
(0.1 - 0.4(%))
Talento AF, 2010
HCV (anti-HCV)
0.1 (%)
2009
(0 - 0.4(%))
Talento AF, 2010

Hepatitis related deaths (national)

Modelled

HBV
61
2019
(47 - 80)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
168
2019
(133 - 204)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.04(%))
IHME

Prevalence PWID

HCV
41.50 (%)
2010, survey/surveillance
(34.60 - 48.70(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
46
2014
(37 - 62)
Health Research Board, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources